Genscript Biotech (1548) Stock Forecast & Price Target

Compare

8 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1548 Analyst Ratings

Moderate Buy

1 Buy

0 Hold

0 Sell

Based on 1 analysts giving stock ratings to

Genscript

Biotech

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1548 Stock 12 Month Forecast

Average Price Target

HK$23.99

▲(41.27% Upside)

Based on 1 Wall Street analysts offering 12 month price targets for Genscript Biotech in the last 3 months. The average price target is HK$23.99 with a high forecast of HK$23.99 and a low forecast of HK$23.99. The average price target represents a 41.27% change from the last price of HK$16.98.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"HK$9","24":"HK$24","12.75":"HK$12.75","16.5":"HK$16.5","20.25":"HK$20.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":23.987725762,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$23.99</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.987725762,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$23.99</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.987725762,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$23.99</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,12.75,16.5,20.25,24],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2022","6":"May<br/>2024","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.6,17.168286597076925,17.73657319415385,18.30485979123077,18.873146388307692,19.441432985384616,20.00971958246154,20.578006179538463,21.146292776615386,21.71457937369231,22.28286597076923,22.851152567846153,23.419439164923077,{"y":23.987725762,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.6,17.168286597076925,17.73657319415385,18.30485979123077,18.873146388307692,19.441432985384616,20.00971958246154,20.578006179538463,21.146292776615386,21.71457937369231,22.28286597076923,22.851152567846153,23.419439164923077,{"y":23.987725762,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.6,17.168286597076925,17.73657319415385,18.30485979123077,18.873146388307692,19.441432985384616,20.00971958246154,20.578006179538463,21.146292776615386,21.71457937369231,22.28286597076923,22.851152567846153,23.419439164923077,{"y":23.987725762,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.14,"date":1635724800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15.14,"date":1638316800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15.14,"date":1640995200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15.14,"date":1640995200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":15.14,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.14,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.64,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.78,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.92,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.46,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.8,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":16.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetHK$23.99

Average Price TargetHK$23.99

Lowest Price TargetHK$23.99

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yang Huang

J.P. Morgan

HK$16→HK$24

Buy

41.34%

Upside

Reiterated

08/21/25

J.P. Morgan Reaffirms Their Buy Rating on Genscript Biotech (GNNSF)

Dex Genotek

TR | OpenAI - 4o

HK$20

Buy

17.79%

Upside

Upgraded

08/19/25

AI Generated ArticleAI Generated Article

Unknown Analyst

Morgan Stanley

Not Ranked

Morgan Stanley

HK$18.6→HK$21.9

Buy

28.98%

Upside

Reiterated

03/14/25

We lift our PT for GenScript and maintain our OW rating on the company due to three things: 1) GenScript's leading-edge technology platform and industry position in protein and the gene synthesis area with limited qualified competitors; 2) recovery order trend in the CRO and CDMO segments with eased geopolitical overhangs, and 3) outperforming enzyme business thanks to growing wallet share from key account clients as well as accelerated ex-China market expansion.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yang Huang

J.P. Morgan

HK$16→HK$24

Buy

41.34%

Upside

Reiterated

08/21/25

J.P. Morgan Reaffirms Their Buy Rating on Genscript Biotech (GNNSF)

Dex Genotek

TR | OpenAI - 4o

HK$20

Buy

17.79%

Upside

Upgraded

08/19/25

AI Generated ArticleAI Generated Article

Unknown Analyst

Morgan Stanley

Not Ranked

Morgan Stanley

HK$18.6→HK$21.9

Buy

28.98%

Upside

Reiterated

03/14/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Genscript Biotech

1 Month

xxx

Success Rate

0/2 ratings generated profit

Average Return

-8.45%

upgraded a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 0.00% of your transactions generating a profit, with an average return of -8.45% per trade.

3 Months

xxx

Success Rate

1/2 ratings generated profit

Average Return

+1.40%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +1.40% per trade.

1 Year

Yang HuangJ.P. Morgan

Success Rate

0/2 ratings generated profit

Average Return

-7.50%

reiterated a buy rating 9 days ago

Copying Yang Huang's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -7.50% per trade.

2 Years

xxx

Success Rate

1/2 ratings generated profit

Average Return

+18.95%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +18.95% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1548 Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1548 has received 2 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. 1548 average Analyst price target in the past 3 months is 23.99.

Each month's total comprises the sum of three months' worth of ratings.

1548 Financial Forecast

1548 Earnings Forecast

Next quarter’s earnings estimate for 1548 is -HK$0.08 with a range of -HK$0.08 to -HK$0.08. The previous quarter’s EPS was -HK$0.17. 1548 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.10% of the time in the same period. In the last calendar year 1548 has Outperformed its overall industry.

1548 Sales Forecast

Next quarter’s sales forecast for 1548 is HK$3.44B with a range of HK$3.44B to HK$3.44B. The previous quarter’s sales results were HK$4.04B. 1548 beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.91% of the time in the same period. In the last calendar year 1548 has Preformed in-line its overall industry.

1548 Stock Forecast FAQ

What is HK:1548’s average 12-month price target, according to analysts?

Based on analyst ratings, Genscript Biotech Corporation’s 12-month average price target is 23.99.

What is HK:1548’s upside potential, based on the analysts’ average price target?

Genscript Biotech Corporation has 41.27% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Genscript Biotech Corporation a Buy, Sell or Hold?

Genscript Biotech Corporation has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.

What is Genscript Biotech Corporation’s share price target?

The average share price target for Genscript Biotech Corporation is 23.99. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$23.99 ,and the lowest forecast is HK$23.99. The average share price target represents 41.27% Increase from the current price of HK$16.98.

What do analysts say about Genscript Biotech Corporation?

Genscript Biotech Corporation’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of Genscript Biotech Corporation?

To buy shares of HK:1548, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Genscript Biotech (1548) Stock Forecast & Price Target

1548 Analyst Ratings

1548 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Genscript Biotech

1548 Analyst Recommendation Trends

1548 Financial Forecast

1548 Earnings Forecast

1548 Sales Forecast

1548 Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts